


Pomalidomide-d₅

Cat. No.:	HY-10984S
CAS No.:	1377838-49-7
Molecular Formula:	C ₁₃ H ₆ D ₅ N ₃ O ₄
Molecular Weight:	278.27
Target:	Apoptosis; Ligands for E3 Ligase; Molecular Glues; Isotope-Labeled Compounds
Pathway:	Apoptosis; PROTAC; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pomalidomide-d ₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.	
IC₅₀ & Target	Cereblon	Cereblon
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. Hernandez-Illizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. *Clin Cancer Res.* 2005 Aug 15;11(16):5984-92.
- [2]. Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. *PLoS One.* 2013 Aug 5;8(8):e71754.
- [3]. Liu D, et al. Tumour necrosis factor- α inhibits hepatic lipid deposition through GSK-3 β / β -catenin signaling in juvenile turbot (*Scophthalmus maximus* L.). *Gen Comp Endocrinol.* 2016 Mar 1;228:1-8.
- [4]. Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. *Chem Biol.* 2015 Jun 18;22(6):755-63.
- [5]. Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. *J Pharmacol Exp Ther.* 2003 Jun;305(3):1222-32.
- [6]. Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. *Leuk Lymphoma.* 2013 Apr;54(4):683-7.
- [7]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA